
GSK appoints Emma Walmsley as CEO
pharmafile | September 20, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | GSK, GlaxoSmithKline, appointment
GlaxoSmithKline, the UK’s biggest drugs company, has appointed Emma Walmsley as its new CEO. Walmsley will step into the vacancy left by current CEO Sir Andrew Witty who will step down in March 2017.
Walmsley joined the company in 2010 and oversees its consumer healthcare division. She had previously served at L’Oreal for 17 years, working in the UK, Europe, China and the US. She now becomes the most powerful woman in the FTSE100 and one of just six female chief executives.
Hampton said: “Emma is an outstanding leader with highly valuable experience of building and running major global businesses and a strong track record of delivering growth and driving performance in healthcare.”
Walmsley said: “I am delighted and honoured to be appointed GSK’s next CEO. I’m looking forward to working with Andrew and other leaders over the next few months to ensure a smooth handover and to develop plans for 2017 and beyond.”
Matt Fellows
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.





